Abiopharma

🔍 Gharib Samir M. (Executive)

Company: SPRUCE BIOSCIENCES, INC. (SPRB)

Report Date: 2025-12-11

Detailed Transactions and Holdings:

• Acquired 1,579 shares of Stock Option (Right to Buy) at $104.13 per share (Derivative)
  Date: 2025-12-11 | Code: A | Expires: 2030-06-07 | equity_swap_involved: 0 | shares_owned_after: 1,579.00 | transaction_form_type: 4 | Footnotes: F2, F1
• Sold 1,579 shares of Stock Option (Right to Buy) at $123.0 per share (Derivative)
  Date: 2025-12-11 | Code: D | Expires: 2030-06-07 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F2, F1
• Acquired 953 shares of Stock Option (Right to Buy) at $104.13 per share (Derivative)
  Date: 2025-12-11 | Code: A | Expires: 2030-08-06 | equity_swap_involved: 0 | shares_owned_after: 953.00 | transaction_form_type: 4 | Footnotes: F2, F1
• Sold 953 shares of Stock Option (Right to Buy) at $230.25 per share (Derivative)
  Date: 2025-12-11 | Code: D | Expires: 2030-08-06 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F2, F1
• Acquired 733 shares of Stock Option (Right to Buy) at $104.13 per share (Derivative)
  Date: 2025-12-11 | Code: A | Expires: 2031-01-27 | equity_swap_involved: 0 | shares_owned_after: 733.00 | transaction_form_type: 4 | Footnotes: F2, F1
• Sold 733 shares of Stock Option (Right to Buy) at $1506.0 per share (Derivative)
  Date: 2025-12-11 | Code: D | Expires: 2031-01-27 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F2, F1
• Acquired 1,933 shares of Stock Option (Right to Buy) at $104.13 per share (Derivative)
  Date: 2025-12-11 | Code: A | Expires: 2031-12-15 | equity_swap_involved: 0 | shares_owned_after: 1,933.00 | transaction_form_type: 4 | Footnotes: F2, F4
• Sold 1,933 shares of Stock Option (Right to Buy) at $186.0 per share (Derivative)
  Date: 2025-12-11 | Code: D | Expires: 2031-12-15 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F2, F4
• Acquired 933 shares of Stock Option (Right to Buy) at $104.13 per share (Derivative)
  Date: 2025-12-11 | Code: A | Expires: 2032-01-02 | equity_swap_involved: 0 | shares_owned_after: 933.00 | transaction_form_type: 4 | Footnotes: F2, F5
• Sold 933 shares of Stock Option (Right to Buy) at $344.25 per share (Derivative)
  Date: 2025-12-11 | Code: D | Expires: 2032-01-02 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F2, F5

Footnotes:

• F1: The shares subject to the option are fully vested and exercisable.
• F2: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 11, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date.
• F3: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options.
• F4: 1/48th of the shares vest on a monthly basis from December 16, 2021, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan).
• F5: 1/48th of the shares vest on a monthly basis from January 3, 2022, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan).